Targeted Combination Therapy Triggers Cell Death in Mouse Models of Metastatic Cancer
Wednesday, April 30, 2008 - 13:55
in Health & Medicine
A combination of two targeted drugs--one that blocks protein breakdown and one that activates the programmed cell death pathway--reduces the number of tumor metastases in mouse models of kidney and breast cancer. The combination also prolonged overall survival in mice with kidney cancer. Bortezomib blocks the activity of the proteasome, an enzyme complex which degrades misfolded or unwanted proteins. Bortezomib has been approved by the U.S. Food and Drug Administration for the treatment of multiple myeloma, but its activity against solid tumors is still being tested.
Read the whole article on Science Daily
More from Science Daily
Related
- 2-drug combination appears safe and active in metastatic kidney cancerSun, 31 May 2009, 14:36:34 EDT
- Licorice extract blocks colorectal cancer in miceMon, 23 Mar 2009, 17:38:57 EDT
- Scientists create mouse model of melanoma that generates hope for the use of targeted therapiesThu, 12 Mar 2009, 16:58:08 EDT
- Potent metastasis inhibitor identifiedMon, 22 Jun 2009, 18:50:50 EDT
- New cancer treatment targets both tumor cells and blood vesselsWed, 18 Jun 2008, 12:21:21 EDT